{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:21:56Z","timestamp":1791908516366,"version":"4.3.4"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2023,4,30]],"date-time":"2023-04-30T00:00:00Z","timestamp":1682812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"AnaptysBio"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,7,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Generalized pustular psoriasis (GPP) is a systemic inflammatory disease that can be severe, debilitating and life threatening. Uncontrolled activation of interleukin (IL)-36 proinflammatory activity may underlie the pathogenesis of GPP. Currently, GPP-specific treatment options are limited.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To evaluate the efficacy and safety of the anti-IL-36 receptor antibody imsidolimab in patients with GPP.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>In an open-label, single-arm, multiple-dose study, patients with GPP were treated with imsidolimab to assess clinical efficacy, tolerability and safety. Patients received an intravenous dose of imsidolimab 750\u2005mg on day 1, followed by three subcutaneous doses of imsidolimab 100\u2005mg administered on days 29, 57 and 85. The primary efficacy endpoint was the proportion of patients who achieved a clinical response at weeks 4 and 16 following treatment with imsidolimab, as measured by the Clinical Global Impression scale.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Eight patients were enrolled and six completed the study. Responses were observed as early as day 3, most rapidly for pustulation relative to other manifestations of GPP, with continued and consistent improvement across multiple efficacy assessments at day 8, day 29 and through day 113. Most treatment-emergent adverse events (TEAEs) were mild to moderate in severity. No patient discontinued the study owing to a nonserious TEAE. Two patients experienced serious adverse events (SAEs); no deaths were reported.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Imsidolimab demonstrated a rapid and sustained resolution of symptoms and pustular eruptions in patients with GPP. It was generally well tolerated, with an acceptable safety profile, and is advancing to phase III trials. These data support the targeting of IL-36 signalling with a specific antibody \u2013 imsidolimab \u2013 as a therapeutic option for this severely debilitating condition.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/bjd\/ljad083","type":"journal-article","created":{"date-parts":[[2023,4,30]],"date-time":"2023-04-30T08:40:30Z","timestamp":1682844030000},"page":"161-169","source":"Crossref","is-referenced-by-count":61,"title":["Imsidolimab, an anti-interleukin-36 receptor monoclonal antibody, for the treatment of generalized pustular psoriasis: results from the phase II GALLOP trial"],"prefix":"10.1093","volume":"189","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2918-6481","authenticated-orcid":false,"given":"Richard B","family":"Warren","sequence":"first","affiliation":[{"name":"Dermatology Centre, Northern Care Alliance NHS Foundation Trust, NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre , Manchester , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Reich","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Institute of Medical Sciences, Medical College of Rzeszow University , Rzeszow , Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej","family":"Kaszuba","sequence":"additional","affiliation":[{"name":"DERMED Centrum Medyczne Sp. z o.o. , Lodz , Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waldemar","family":"Placek","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Sexually Transmitted Diseases and Clinical Immunology Collegium Medicum University of Varmia and Mazury , Olsztyn , Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher E M","family":"Griffiths","sequence":"additional","affiliation":[{"name":"Dermatology Centre, Northern Care Alliance NHS Foundation Trust, NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre , Manchester , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihao","family":"Zhou","sequence":"additional","affiliation":[{"name":"AnaptysBio, Inc. , San Diego, CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Randazzo","sequence":"additional","affiliation":[{"name":"AnaptysBio, Inc. , San Diego, CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Lizzul","sequence":"additional","affiliation":[{"name":"AnaptysBio, Inc. , San Diego, CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann E","family":"Gudjonsson","sequence":"additional","affiliation":[{"name":"University of Michigan, Department of Dermatology , Ann Arbor, MI , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,4,30]]},"reference":[{"key":"2023122117335088600_ljad083-B1","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/j.1365-2133.1968.tb11947.x","article-title":"Generalized pustular psoriasis. A clinical and epidemiological study of 104 cases","volume":"80","author":"Baker","year":"1968","journal-title":"Br J Dermatol"},{"key":"2023122117335088600_ljad083-B2","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1001\/archderm.1991.01680080075005","article-title":"Generalized pustular psoriasis: a review of 63 cases","volume":"127","author":"Zelickson","year":"1991","journal-title":"Arch Dermatol"},{"key":"2023122117335088600_ljad083-B3","doi-asserted-by":"crossref","first-page":"443","DOI":"10.2340\/0001555572443444","article-title":"Juvenile generalized pustular psoriasis in a pair of monozygotic twins presenting strikingly similar clinical courses","volume":"72","author":"Takematsu","year":"1992","journal-title":"Acta Derm Venereol"},{"key":"2023122117335088600_ljad083-B4","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.clindermatol.2007.08.003","article-title":"The clinical spectrum of psoriasis","volume":"25","author":"Naldi","year":"2007","journal-title":"Clin Dermatol"},{"key":"2023122117335088600_ljad083-B5","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.jaad.2011.01.032","article-title":"Treatment of pustular psoriasis: from the Medical Board of the National Psoriasis Foundation","volume":"67","author":"Robinson","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"2023122117335088600_ljad083-B6","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2165\/11586900-000000000-00000","article-title":"Clinical and laboratory features in acute generalized pustular psoriasis: a retrospective study of 34 patients","volume":"12","author":"Borges-Costa","year":"2011","journal-title":"Am J Clin Dermatol"},{"key":"2023122117335088600_ljad083-B7","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/ijd.12070","article-title":"Clinical profile, morbidity, and outcome of adult-onset generalized pustular psoriasis: analysis of 102 cases seen in a tertiary hospital in Johor, Malaysia","volume":"53","author":"Choon","year":"2014","journal-title":"Int J Dermatol"},{"key":"2023122117335088600_ljad083-B8","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1111\/jdv.14949","article-title":"Generalized pustular psoriasis: a review and update on treatment","volume":"32","author":"Hoegler","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2023122117335088600_ljad083-B9","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1365-2230.2006.02315.x","article-title":"Flare and change of psoriasis morphology during the course of treatment with tumour necrosis factor blockers","volume":"32","author":"Goiriz","year":"2007","journal-title":"Clin Exp Dermatol"},{"key":"2023122117335088600_ljad083-B10","first-page":"131","article-title":"Pustular psoriasis: pathophysiology and current treatment perspectives","volume":"12","author":"Benjegerdes","year":"2016","journal-title":"Psoriasis (Auckl"},{"key":"2023122117335088600_ljad083-B11","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1111\/jdv.14386","article-title":"European consensus statement on phenotypes of pustular psoriasis","volume":"31","author":"Navarini","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2023122117335088600_ljad083-B12","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1038\/jid.2012.490","article-title":"Rare pathogenic variants in IL36RN underlie a spectrum of psoriasis-associated pustular phenotypes","volume":"133","author":"Setta-Kaffetzi","year":"2013","journal-title":"J Invest Dermatol"},{"key":"2023122117335088600_ljad083-B13","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41423-020-0519-3","article-title":"\u201cAutoinflammatory psoriasis\u201d \u2013 genetics and biology of pustular psoriasis","volume":"18","author":"Uppala","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"2023122117335088600_ljad083-B14","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22169048","article-title":"Generalized pustular psoriasis: divergence of innate and adaptive immunity","volume":"22","author":"Samotij","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2023122117335088600_ljad083-B15","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1056\/NEJMoa1013068","article-title":"Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis","volume":"365","author":"Marrakchi","year":"2011","journal-title":"N Engl J Med"},{"key":"2023122117335088600_ljad083-B16","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.ajhg.2011.07.022","article-title":"Mutations in IL36RN\/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasis","volume":"89","author":"Onoufriadis","year":"2011","journal-title":"Am J Hum Genet"},{"key":"2023122117335088600_ljad083-B17","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/j.1365-2133.2012.10953.x","article-title":"A novel IL36RN\/IL1F5 homozygous nonsense mutation, p.Arg10X, in a Japanese patient with adult onset generalized pustular psoriasis","volume":"167","author":"Sugiura","year":"2012","journal-title":"Br J Dermatol"},{"key":"2023122117335088600_ljad083-B18","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1038\/jid.2013.267","article-title":"Prevalent and rare mutations in IL-36RN gene in Chinese patients with generalized pustular psoriasis and psoriasis vulgaris","volume":"133","author":"Li","year":"2013","journal-title":"J Invest Dermatol"},{"key":"2023122117335088600_ljad083-B19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.det.2014.09.001","article-title":"Genetics of psoriasis","volume":"33","author":"Mahil","year":"2015","journal-title":"Dermatol Clin"},{"key":"2023122117335088600_ljad083-B20","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.4049\/jimmunol.167.3.1440","article-title":"Two novel IL-1 family members, IL-1 delta and IL-1 epsilon, function as an antagonist and agonist of NF-kappa B activation through the orphan IL-1 receptor-related protein 2","volume":"167","author":"Debets","year":"2001","journal-title":"J Immunol"},{"key":"2023122117335088600_ljad083-B21","doi-asserted-by":"crossref","first-page":"13677","DOI":"10.1074\/jbc.M400117200","article-title":"Interleukin (IL)-1F6, IL-1F8, and IL-1F9 signal through IL-1Rrp2 and IL-1RAcP to activate the pathway leading to NF-kappaB and MAPKs","volume":"279","author":"Towne","year":"2004","journal-title":"J Biol Chem"},{"key":"2023122117335088600_ljad083-B22","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/ni1110-973","article-title":"IL-1 family nomenclature","volume":"11","author":"Dinarello","year":"2010","journal-title":"Nat Immunol"},{"key":"2023122117335088600_ljad083-B23","doi-asserted-by":"crossref","first-page":"4354","DOI":"10.4049\/jimmunol.1000313","article-title":"IL-1RL2 and its ligands contribute to the cytokine network in psoriasis","volume":"185","author":"Blumberg","year":"2010","journal-title":"J Immunol"},{"key":"2023122117335088600_ljad083-B24","doi-asserted-by":"crossref","first-page":"10308","DOI":"10.1074\/jbc.275.14.10308","article-title":"Identification and initial characterization of four novel members of the interleukin-1 family","volume":"275","author":"Kumar","year":"2000","journal-title":"J Biol Chem"},{"key":"2023122117335088600_ljad083-B25","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1038\/jid.2013.230","article-title":"The majority of generalized pustular psoriasis without psoriasis vulgaris is caused by deficiency of interleukin-36 receptor antagonist","volume":"133","author":"Sugiura","year":"2013","journal-title":"J Invest Dermatol"},{"key":"2023122117335088600_ljad083-B26","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1038\/jid.2013.214","article-title":"Mutations in IL36RN in patients with generalized pustular psoriasis","volume":"133","author":"K\u00f6rber","year":"2013","journal-title":"J Invest Dermatol"},{"key":"2023122117335088600_ljad083-B27","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.jaci.2014.09.043","article-title":"IL36RN mutations define a severe autoinflammatory phenotype of generalized pustular psoriasis","volume":"135","author":"Hussain","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"2023122117335088600_ljad083-B28","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jaci.2016.08.056","article-title":"IL-1 and IL-36 are dominant cytokines in generalized pustular psoriasis","volume":"140","author":"Johnston","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"2023122117335088600_ljad083-B29","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMc1811317","article-title":"Inhibition of the interleukin-36 pathway for the treatment of generalized pustular psoriasis","volume":"380","author":"Bachelez","year":"2019","journal-title":"N Engl J Med"},{"key":"2023122117335088600_ljad083-B30","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology Life Quality Index (DLQI) \u2013 a simple practical measure for routine clinical use","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin Exp Dermatol"},{"key":"2023122117335088600_ljad083-B31","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1080\/1744666X.2019.1648209","article-title":"An update on generalized pustular psoriasis","volume":"15","author":"Gooderham","year":"2019","journal-title":"Expert Rev Clin Immunol"},{"key":"2023122117335088600_ljad083-B32","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1111\/1346-8138.14523","article-title":"Japanese guidelines for the management and treatment of generalized pustular psoriasis: the new pathogenesis and treatment of GPP","volume":"45","author":"Fujita","year":"2018","journal-title":"J Dermatol"},{"key":"2023122117335088600_ljad083-B33","first-page":"2211","article-title":"Practice guidelines 2014 for generalized pustular psoriasis (GPP)","volume":"125","author":"Terui","year":"2015","journal-title":"Jpn J Dermatol"},{"key":"2023122117335088600_ljad083-B34","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1056\/NEJMoa2111563","article-title":"Trial of spesolimab for generalized pustular psoriasis","volume":"385","author":"Bachelez","year":"2021","journal-title":"N Engl J Med"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljad083\/50847450\/ljad083.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/189\/2\/161\/54726252\/ljad083.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/189\/2\/161\/54726252\/ljad083.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T19:14:14Z","timestamp":1703186054000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/189\/2\/161\/7147294"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,30]]},"references-count":34,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,4,30]]},"published-print":{"date-parts":[[2023,7,17]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljad083","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,8]]},"published":{"date-parts":[[2023,4,30]]}}}